Searches for beyond Standard Model Higgs bosons at CMS

A search for neutral Higgs bosons in the minimal supersymmetric extension of the Standard Model (MSSM) decaying to a pair of b quarks or a pair of tau leptons, using events recorded by the CMS experiment at the LHC in 2011 and 2012 at the centre-of-mass energy of 7 TeV and 8 TeV respectively, is presented. The result is also presented for a search for the charged Higgs boson that can be produced in the top quark decay with subsequent decay of H+ in tau and neutrino. Results are also reported from a search for non-standard-model Higgs boson decays to pairs of new light bosons, each of which decays into the di-muon final state.Comment: Submitted to the proceedings of "The European Physical Society Conference on High Energy Physics - EPS-HEP2013, 18-24 July 2013,Stockholm, Sweden

Measurement of the Z boson plus two b-jets cross section in CMS with 100 pb-1

The cross section for production of Z bosons with two associated b-jets, and Z decaying to leptons, can be measured at the LHC with about 100 pb-1 of data. We use simulated data to study possible strategies for an early measurement of this process with the CMS detector. The rate and kinematic properties of this final state needs to be well understood because it constitutes a large fraction of the total backgrounds to several of the Higgs discovery channels at the LHC.Comment: 5 pages, 3 figures, submitted to the proceedings of Physics at LHC 2008, Split, Croati

Improving Heavy Dijet Resonance Searches Using Jet Substructure at the LHC

The search for new physics at high energy accelerators has been at the crossroads with very little hint of signals suggesting otherwise. The challenges at a hadronic machine such as the LHC compounds on the fact that final states are swamped with jets which one needs to understand and unravel. A positive step in this direction would be to separate the jets in terms of their gluonic and quark identities, much in similar spirit of distinguishing heavy quark jets from light quark jets that has helped in improving searches for both neutral and charged Higgs bosons at the LHC. In this work, we utilise this information using the jet substructure techniques to comment on possible improvements in sensitivity as well as discrimination of new resonances in the all hadronic mode that would be crucial in pinning down new physics signals at HL-LHC, HE-LHC and any future 100 TeV hadron collider.Comment: 21 pages, 3 tables, 9 figure

Leptoquark-assisted Singlet-mediated Di-Higgs Production at the LHC

At the LHC, the gluon-initiated processes are considered to be the primary source of di-Higgs production. However, in the presence of a new resonance, the light-quark initiated processes can also contribute significantly. In this paper, we look at the di-Higgs production mediated by a new singlet scalar. The singlet is produced in both quark-antiquark and gluon fusion processes through loops involving a scalar leptoquark and right-handed neutrinos. With benchmark parameters inspired from the recent resonant di-Higgs searches by the ATLAS collaboration, we examine the prospects of such a resonance in the TeV-range at the High-Luminosity LHC (HL-LHC) in the $b\bar{b} \tau^{+}\tau^{-}$ mode with a multivariate analysis. We obtain the $5\sigma$ and $2\sigma$ contours and find that a significant part of the parameter space is within the reach of the HL-LHC.Comment: 11 pages, 7 figures, 3 tables. Published versio

ROLE OF PROTECTION PROVIDED BY EMBLICA OFFICINALIS LINN. AGAINST RADIATION AND LEAD INDUCED HISTOLOGICAL CHANGES IN THE JEJUNUM OF SWISS ALBINO MICE

oai:ojs.pkp.sfu.ca:article/1Exposure to ionizing radiation increases the production of the reactive oxygen species (ROS) leading the irradiated cells into a state of oxidative stress. Furthermore, Lead exposure along with ionizing radiation can potentially become toxic to the tissues due to the heightened oxidative stress. In the present study adult male Swiss albino mice were procured and divided into seven groups. Group (II to IV) serving as control, received sub lethal dose (3.0 Gy or 6.0Gy) and /or lead acetate (20ppm) in drinking water ad libitum. The experimental groups (V to VII) were given aqueous solution of Emblica (1000 mg/ Kg b.wt./ animal/ day) orally seven days prior to radiation and/or lead acetate treatment. Sham- irradiated animals of Group I served as normal. Animals of all the groups were autopsied at each post treatment interval of 1, 2, 4, 7, 14 and 28 days. After the experiments observed number of lesions in the intestinal epithelium from outer coat to inner mucosa. Loosened sub mucosa with hyperaemia and hemorrhage, shortened crypts and a number of apoptotic cells with severe cytoplasmic variations were noted. Villi had a rough surface, wavy epithelium and hydropic degeneration up to day-2 and thereafter, a recovery from intestinal lesions was initiated and noticed till the last autopsy interval. After the combined exposure of gamma radiation and lead acetate, Group IV exhibited same pattern of damage but severe histopathological alteration than individual exposure of radiation or lead acetate indicating “synergistic “effect. Process of recovery started on day-14 after the combined treatment but the process was slow. The Combined treatment showed synergistic effect. In experimental groups less severe radiolesions and an early onset of recovery was observed. Therefore it may be deduced that Emblica is a good herbal radioprotector and may be useful for the clinical applications in human beings during radiotherapy.

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019 : A systematic analysis for the Global Burden of Disease Study 2019

Background Achieving universal health coverage (UHC) involves all people receiving the health services they need, of high quality, without experiencing financial hardship. Making progress towards UHC is a policy priority for both countries and global institutions, as highlighted by the agenda of the UN Sustainable Development Goals (SDGs) and WHO's Thirteenth General Programme of Work (GPW13). Measuring effective coverage at the health-system level is important for understanding whether health services are aligned with countries' health profiles and are of sufficient quality to produce health gains for populations of all ages. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we assessed UHC effective coverage for 204 countries and territories from 1990 to 2019. Drawing from a measurement framework developed through WHO's GPW13 consultation, we mapped 23 effective coverage indicators to a matrix representing health service types (eg, promotion, prevention, and treatment) and five population-age groups spanning from reproductive and newborn to older adults (≥65 years). Effective coverage indicators were based on intervention coverage or outcome-based measures such as mortality-to-incidence ratios to approximate access to quality care; outcome-based measures were transformed to values on a scale of 0–100 based on the 2·5th and 97·5th percentile of location-year values. We constructed the UHC effective coverage index by weighting each effective coverage indicator relative to its associated potential health gains, as measured by disability-adjusted life-years for each location-year and population-age group. For three tests of validity (content, known-groups, and convergent), UHC effective coverage index performance was generally better than that of other UHC service coverage indices from WHO (ie, the current metric for SDG indicator 3.8.1 on UHC service coverage), the World Bank, and GBD 2017. We quantified frontiers of UHC effective coverage performance on the basis of pooled health spending per capita, representing UHC effective coverage index levels achieved in 2019 relative to country-level government health spending, prepaid private expenditures, and development assistance for health. To assess current trajectories towards the GPW13 UHC billion target—1 billion more people benefiting from UHC by 2023—we estimated additional population equivalents with UHC effective coverage from 2018 to 2023. Findings Globally, performance on the UHC effective coverage index improved from 45·8 (95% uncertainty interval 44·2–47·5) in 1990 to 60·3 (58·7–61·9) in 2019, yet country-level UHC effective coverage in 2019 still spanned from 95 or higher in Japan and Iceland to lower than 25 in Somalia and the Central African Republic. Since 2010, sub-Saharan Africa showed accelerated gains on the UHC effective coverage index (at an average increase of 2·6% [1·9–3·3] per year up to 2019); by contrast, most other GBD super-regions had slowed rates of progress in 2010–2019 relative to 1990–2010. Many countries showed lagging performance on effective coverage indicators for non-communicable diseases relative to those for communicable diseases and maternal and child health, despite non-communicable diseases accounting for a greater proportion of potential health gains in 2019, suggesting that many health systems are not keeping pace with the rising non-communicable disease burden and associated population health needs. In 2019, the UHC effective coverage index was associated with pooled health spending per capita (r=0·79), although countries across the development spectrum had much lower UHC effective coverage than is potentially achievable relative to their health spending. Under maximum efficiency of translating health spending into UHC effective coverage performance, countries would need to reach $1398 pooled health spending per capita (US$ adjusted for purchasing power parity) in order to achieve 80 on the UHC effective coverage index. From 2018 to 2023, an estimated 388·9 million (358·6–421·3) more population equivalents would have UHC effective coverage, falling well short of the GPW13 target of 1 billion more people benefiting from UHC during this time. Current projections point to an estimated 3·1 billion (3·0–3·2) population equivalents still lacking UHC effective coverage in 2023, with nearly a third (968·1 million [903·5–1040·3]) residing in south Asia. Interpretation The present study demonstrates the utility of measuring effective coverage and its role in supporting improved health outcomes for all people—the ultimate goal of UHC and its achievement. Global ambitions to accelerate progress on UHC service coverage are increasingly unlikely unless concerted action on non-communicable diseases occurs and countries can better translate health spending into improved performance. Focusing on effective coverage and accounting for the world's evolving health needs lays the groundwork for better understanding how close—or how far—all populations are in benefiting from UHC

Optimasi Portofolio Resiko Menggunakan Model Markowitz MVO Dikaitkan dengan Keterbatasan Manusia dalam Memprediksi Masa Depan dalam Perspektif Al-Qur`an

Risk portfolio on modern finance has become increasingly technical, requiring the use of sophisticated mathematical tools in both research and practice. Since companies cannot insure themselves completely against risk, as human incompetence in predicting the future precisely that written in Al-Quran surah Luqman verse 34, they have to manage it to yield an optimal portfolio. The objective here is to minimize the variance among all portfolios, or alternatively, to maximize expected return among all portfolios that has at least a certain expected return. Furthermore, this study focuses on optimizing risk portfolio so called Markowitz MVO (Mean-Variance Optimization). Some theoretical frameworks for analysis are arithmetic mean, geometric mean, variance, covariance, linear programming, and quadratic programming. Moreover, finding a minimum variance portfolio produces a convex quadratic programming, that is minimizing the objective function ðð¥with constraintsð ð 𥠥 ðandð´ð¥ = ð. The outcome of this research is the solution of optimal risk portofolio in some investments that could be finished smoothly using MATLAB R2007b software together with its graphic analysis